Novel combination therapy for rheumatoid arthritis: efficacy of anti-CD3 antibody enhanced by p38 inhibitor (Work packages 1-4)
Novel combination therapy for rheumatoid arthritis: efficacy of anti-CD3 antibody enhanced by p38 inhibitor (Work packages 1-4)
批准号:
MR/P50208X/1
负责人:
Michael Ehrenstein
金额:
$19.24万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --
中文摘要
抗CD3疗法有可能在短暂的疗程后对1型糖尿病患者具有长期疗效,如果转化为RA的治疗,可能会减少甚至消除频繁的生物治疗的需要,并带来所有相关的财务和医疗保健好处。然而,其进入临床的途径一直受到各种反应和副作用的阻碍,后者是由炎性细胞因子释放引起的。本申请概述了一项机制验证研究,以确定联合应用炎性结蛋白激酶p38的抑制剂是否可以减轻抗CD3治疗性抗体Otelixizumab(OTX)的副作用并增强临床反应。
英文摘要
Anti-CD3 therapy has the potential to have long-lasting efficacy for patients with type 1 diabetes following a brief course of therapy, which if translated to the treatment of RA could reduce or even remove the need for frequent biologic therapy with all the associated financial and healthcare benefits. However, its pathway into the clinic has been hampered by variable responses and side effects, the latter caused by inflammatory cytokine release. This application outlines a proof-of-mechanism study to determine whether the side effects of the anti-CD3 therapeutic antibody Otelixizumab (OTX) could be mitigated and clinical response enhanced, by co-administration of an inhibitor of the inflammatory nodal kinase p38.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the role of LAG3 in regulatory and effector T cells in systemic lupus erythematosus
-
批准号:MR/V033573/1
-
项目类别:Research Grant
-
资助金额:$15.51万
-
财政年份:2021
-
负责人:Michael Ehrenstein
-
依托单位:
海外基金